Erythropoiesis in cancer patients undergoing immunotherapy

J. L. Ascensao, S. J. Liu, J. Caro, E. Podack, A. Mittelman, E. D. Zanjani, Y. L. Zhao

Research output: Chapter in Book/Report/Conference proceedingConference contribution

3 Scopus citations


We studied ten patients with various types of cancer who were being treated with Interleukin-2 (IL-2) and lymphokine activated killer cells (LAK). All patients developed a reticulocytopenic, normochromic, normocytic anemia. We noted some variability but no significant suppression of circulating erythroid progenitors. The levels of erythropoietin were lower than expected for the hemoglobin/hematocrit values. We could not detect Interferon or Tumor Necrosis Factor (TNF) in the serum of these patients; however, the supernatant of LAK cells did contain Interferon and TNF which could be neutralized with appropriate antibodies. These results suggest that the etiology of this anemia is multi-factorial. Administration of recombinant erythropoietin (Ep) may be of benefit in some of these patients.

Original languageEnglish (US)
Title of host publicationAdvances in Experimental Medicine and Biology
Number of pages8
StatePublished - Oct 2 1990

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)


Dive into the research topics of 'Erythropoiesis in cancer patients undergoing immunotherapy'. Together they form a unique fingerprint.

Cite this